NasdaqCM - Delayed Quote USD

Biofrontera Inc. (BFRI)

1.5900 -0.1200 (-7.02%)
At close: April 26 at 4:00 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
34,071.0000
34,071.0000
28,674.0000
24,100.0000
18,849.0000
Cost of Revenue
17,444.0000
17,444.0000
15,185.0000
12,742.0000
9,066.0000
Gross Profit
16,627.0000
16,627.0000
13,489.0000
11,358.0000
9,783.0000
Operating Expense
39,204.0000
39,204.0000
35,870.0000
37,209.0000
18,117.0000
Operating Income
-22,577.0000
-22,577.0000
-22,381.0000
-25,851.0000
-8,334.0000
Net Non Operating Interest Income Expense
-560.0000
-560.0000
-203.0000
-344.0000
-2,869.0000
Other Income Expense
3,020.0000
3,020.0000
21,976.0000
-11,462.0000
280.0000
Pretax Income
-20,117.0000
-20,117.0000
-608.0000
-37,657.0000
-10,923.0000
Tax Provision
14.0000
14.0000
32.0000
56.0000
64.0000
Net Income Common Stockholders
-20,131.0000
-20,131.0000
-640.0000
-37,713.0000
-10,987.0000
Diluted NI Available to Com Stockholders
-20,131.0000
-20,131.0000
-640.0000
-37,713.0000
-10,987.0000
Basic EPS
-13.02
--
-0.61
-85.60
-18.94
Diluted EPS
-13.02
--
-0.61
-85.60
-18.94
Basic Average Shares
1,546.2970
--
1,056.9880
440.4110
580.0000
Diluted Average Shares
1,546.2970
--
1,056.9880
440.4110
580.0000
Total Operating Income as Reported
-22,677.0000
-22,677.0000
-18,581.0000
-25,201.0000
-9,606.0000
Total Expenses
56,648.0000
56,648.0000
51,055.0000
49,951.0000
27,183.0000
Net Income from Continuing & Discontinued Operation
-20,131.0000
-20,131.0000
-640.0000
-37,713.0000
-10,987.0000
Normalized Income
-22,413.3100
-22,413.3100
-17,946.5300
-28,842.7700
-10,019.7407
Interest Income
132.0000
132.0000
175.0000
16.0000
28.0000
Interest Expense
600.0000
600.0000
370.0000
360.0000
2,897.0000
Net Interest Income
-560.0000
-560.0000
-203.0000
-344.0000
-2,869.0000
EBIT
-19,517.0000
-19,517.0000
-238.0000
-37,297.0000
-8,026.0000
EBITDA
-18,453.0000
-18,453.0000
934.0000
-36,757.0000
-7,464.0000
Reconciled Cost of Revenue
17,444.0000
17,444.0000
15,185.0000
12,742.0000
9,066.0000
Reconciled Depreciation
1,064.0000
1,064.0000
1,172.0000
540.0000
562.0000
Net Income from Continuing Operation Net Minority Interest
-20,131.0000
-20,131.0000
-640.0000
-37,713.0000
-10,987.0000
Total Unusual Items Excluding Goodwill
2,889.0000
2,889.0000
21,907.0000
-12,151.0000
-973.0000
Total Unusual Items
2,889.0000
2,889.0000
21,907.0000
-12,151.0000
-973.0000
Normalized EBITDA
-21,342.0000
-21,342.0000
-20,973.0000
-24,606.0000
-6,491.0000
Tax Rate for Calcs
0.0002
0.0002
0.0002
0.0003
0.0000
Tax Effect of Unusual Items
606.6900
606.6900
4,600.4700
-3,280.7700
-5.7407
12/31/2020 - 10/29/2021

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

PTPI Petros Pharmaceuticals, Inc.
0.6399
0.00%
 
SHPH Shuttle Pharmaceuticals Holdings, Inc.
0.3850
-0.90%
 
SNOA Sonoma Pharmaceuticals, Inc.
0.1590
-1.18%
 
SXTC China SXT Pharmaceuticals, Inc.
1.0500
+1.94%
 
RDHL RedHill Biopharma Ltd.
0.4280
+2.22%
 
SBFM Sunshine Biopharma, Inc.
0.9500
+17.66%
 
LSDI Lucy Scientific Discovery Inc.
0.7597
-12.58%
 
MEDXF Medexus Pharmaceuticals Inc.
1.3850
+2.59%
 
AGRX Agile Therapeutics, Inc.
0.4000
0.00%
 
DERM Journey Medical Corporation
3.4000
-2.86%